Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2015

Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Graft Versus Host Disease (GVHD)-Pipeline Review, H1 2015', provides an overview of the Graft Versus Host Disease (GVHD)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Graft Versus Host Disease (GVHD) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Graft Versus Host Disease (GVHD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Graft Versus Host Disease (GVHD) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Graft Versus Host Disease (GVHD) Overview 10

Therapeutics Development 11

Pipeline Products for Graft Versus Host Disease (GVHD)-Overview 11

Pipeline Products for Graft Versus Host Disease (GVHD)-Comparative Analysis 12

Graft Versus Host Disease (GVHD)-Therapeutics under Development by Companies 13

Graft Versus Host Disease (GVHD)-Therapeutics under Investigation by Universities/Institutes 18

Graft Versus Host Disease (GVHD)-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Graft Versus Host Disease (GVHD)-Products under Development by Companies 23

Graft Versus Host Disease (GVHD)-Products under Investigation by Universities/Institutes 27

Graft Versus Host Disease (GVHD)-Companies Involved in Therapeutics Development 28

AbGenomics International, Inc. 28

Adienne Pharma & Biotech 29

Alder Biopharmaceuticals Inc. 30

Alexion Pharmaceuticals, Inc. 31

Apceth GmbH & Co. KG 32

Athersys, Inc. 33

Bellicum Pharmaceuticals, Inc. 34

Biogen Idec Inc. 35

Dr. Falk Pharma GmbH 36

Enlivex Therapeutics Ltd 37

Escape Therapeutics, Inc. 38

F. Hoffmann-La Roche Ltd. 39

Generon (Shanghai) Corporation Ltd. 40

Idera Pharmaceuticals, Inc. 41

ImmuNext, Inc. 42

Immunomedics, Inc. 43

Jazz Pharmaceuticals plc 44

Kadmon Corporation, LLC 45

Kamada Ltd. 46

Kymab Limited 47

Lycera Corp. 48

Mesoblast Limited 49

Millennium Pharmaceuticals, Inc. 50

MSM Protein Technologies, Inc. 51

Neopharm Ltd. 52

NeoStem, Inc. 53

Novartis AG 54

Omni Bio Pharmaceutical Inc. 55

Pharmacyclics, Inc. 56

Pharmicell Co., Ltd. 57

Pluristem Therapeutics Inc. 58

R-Tech Ueno, Ltd. 59

REGiMMUNE Corporation 60

Rigel Pharmaceuticals, Inc. 61

Sarepta Therapeutics, Inc. 62

Seattle Genetics, Inc. 63

Sigmoid Pharma Limited 64

Soligenix, Inc. 65

Spherium Biomed S.L. 66

Targazyme, Inc. 67

Therapix Biosciences Ltd 68

Tobira Therapeutics, Inc. 69

Xenikos B.V. 70

Graft Versus Host Disease (GVHD)-Therapeutics Assessment 71

Assessment by Monotherapy Products 71

Assessment by Combination Products 72

Assessment by Target 73

Assessment by Mechanism of Action 76

Assessment by Route of Administration 79

Assessment by Molecule Type 81

Drug Profiles 83

AbGn-168H-Drug Profile 83

aldesleukin-Drug Profile 85

Alecmestencel-L-Drug Profile 87

Alpha-1 Antitrypsin-Drug Profile 88

alpha-1 proteinase inhibitor (human)-Drug Profile 89

ALXN-1007-Drug Profile 91

anti-thymocyte globulin (rabbit)-Drug Profile 92

Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD-Drug Profile 94

Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease-Drug Profile 95

ApoCell-Drug Profile 96

beclomethasone dipropionate-Drug Profile 97

begelomab-Drug Profile 99

bortezomib-Drug Profile 100

BPX-501-Drug Profile 105

brentuximab vedotin-Drug Profile 107

budesonide-Drug Profile 112

Bz-423-Drug Profile 115

cannabidiol-Drug Profile 116

Cell Therapy for Autoimmune Diseases and GVHD-Drug Profile 117

Cell Therapy for CNS, Respiratory, Immunology and Metabolic Disorders-Drug Profile 119

Cell Therapy for Graft Versus Host Disease-Drug Profile 120

Cell Therapy for Graft Versus Host Disease-Drug Profile 121

Cell Therapy for Graft Versus Host Disease-Drug Profile 122

Cell Therapy for Graft versus Host Disease-Drug Profile 123

Cell Therapy for Graft-Versus Host Disease-Drug Profile 124

Cell Therapy for GVHD-Drug Profile 125

cenicriviroc mesylate-Drug Profile 126

Cerecellgram for Graft Versus Host Disease-Drug Profile 128

clazakizumab-Drug Profile 129

Coversin-Drug Profile 131

cyclosporine IR + cyclosporine CR-Drug Profile 132

defibrotide-Drug Profile 133

Drugs for Acute and Chronic GVHD-Drug Profile 136

Drugs for Graft Versus Host Disease-Drug Profile 137

erismodegib-Drug Profile 138

F-652-Drug Profile 141

Fc-Alpha-1 Antitrypsin-Drug Profile 142

FcAAT-2-Drug Profile 143

FcAAT-3-Drug Profile 144

Ha-7-Drug Profile 145

ibrutinib-Drug Profile 146

ImmuneSafe-Drug Profile 152

ImmuStem-Drug Profile 153

IMO-8400-Drug Profile 154

inolimomab-Drug Profile 156

IT-603-Drug Profile 157

IT-901-Drug Profile 158

KD-025-Drug Profile 159

KY-1005-Drug Profile 161

milatuzumab-Drug Profile 162

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 164

MSM-707-Drug Profile 166

MultiStem-Drug Profile 167

natalizumab-Drug Profile 170

Oligonucleotide to Inhibit NFAT1 for GVHD-Drug Profile 172

panobinostat-Drug Profile 173

PLX-RAD-Drug Profile 179

Protein to Activate TLR5 for Infectious Disease and GVHD-Drug Profile 182

Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders-Drug Profile 183

Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease-Drug Profile 184

remestemcel-L-Drug Profile 185

RGI-2001-Drug Profile 188

RO-2959-Drug Profile 190

Small Molecule for Graft Versus Host Disease, Hemophagocytic Lymphohistiocytosis and Autoimmune Disorders-Drug Profile 191

Small Molecule to Inhibit Protein Kinase C Theta for Autoimmune Disorder-Drug Profile 192

Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia-Drug Profile 193

Small Molecules to Inhibit SHIP1 for Oncology and Immunology-Drug Profile 194

SP-12008-Drug Profile 195

T-Guard-Drug Profile 196

TZ-101-Drug Profile 198

Graft Versus Host Disease (GVHD)-Recent Pipeline Updates 200

Graft Versus Host Disease (GVHD)-Dormant Projects 283

Graft Versus Host Disease (GVHD)-Discontinued Products 287

Graft Versus Host Disease (GVHD)-Product Development Milestones 288

Featured News & Press Releases 288

Appendix 296

Methodology 296

Coverage 296

Secondary Research 296

Primary Research 296

Expert Panel Validation 296

Contact Us 296

Disclaimer 297

List of Tables

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2015 16

Number of Products under Development for Graft Versus Host Disease (GVHD)-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 19

Number of Products under Development by Companies, H1 2015 (Contd..1) 20

Number of Products under Development by Companies, H1 2015 (Contd..2) 21

Number of Products under Development by Companies, H1 2015 (Contd..3) 22

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Comparative Analysis by Unknown Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Graft Versus Host Disease (GVHD)-Pipeline by AbGenomics International, Inc., H1 2015 33

Graft Versus Host Disease (GVHD)-Pipeline by Adienne Pharma & Biotech, H1 2015 34

Graft Versus Host Disease (GVHD)-Pipeline by Alder Biopharmaceuticals Inc., H1 2015 35

Graft Versus Host Disease (GVHD)-Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 36

Graft Versus Host Disease (GVHD)-Pipeline by Apceth GmbH & Co. KG, H1 2015 37

Graft Versus Host Disease (GVHD)-Pipeline by Athersys, Inc., H1 2015 38

Graft Versus Host Disease (GVHD)-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 39

Graft Versus Host Disease (GVHD)-Pipeline by Biogen Idec Inc., H1 2015 40

Graft Versus Host Disease (GVHD)-Pipeline by Dr. Falk Pharma GmbH, H1 2015 41

Graft Versus Host Disease (GVHD)-Pipeline by Enlivex Therapeutics Ltd, H1 2015 42

Graft Versus Host Disease (GVHD)-Pipeline by Escape Therapeutics, Inc., H1 2015 43

Graft Versus Host Disease (GVHD)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 44

Graft Versus Host Disease (GVHD)-Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 45

Graft Versus Host Disease (GVHD)-Pipeline by Idera Pharmaceuticals, Inc., H1 2015 46

Graft Versus Host Disease (GVHD)-Pipeline by ImmuNext, Inc., H1 2015 47

Graft Versus Host Disease (GVHD)-Pipeline by Immunomedics, Inc., H1 2015 48

Graft Versus Host Disease (GVHD)-Pipeline by Jazz Pharmaceuticals plc, H1 2015 49

Graft Versus Host Disease (GVHD)-Pipeline by Kadmon Corporation, LLC, H1 2015 50

Graft Versus Host Disease (GVHD)-Pipeline by Kamada Ltd., H1 2015 51

Graft Versus Host Disease (GVHD)-Pipeline by Kymab Limited, H1 2015 52

Graft Versus Host Disease (GVHD)-Pipeline by Lycera Corp., H1 2015 53

Graft Versus Host Disease (GVHD)-Pipeline by Mesoblast Limited, H1 2015 54

Graft Versus Host Disease (GVHD)-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 55

Graft Versus Host Disease (GVHD)-Pipeline by MSM Protein Technologies, Inc., H1 2015 56

Graft Versus Host Disease (GVHD)-Pipeline by Neopharm Ltd., H1 2015 57

Graft Versus Host Disease (GVHD)-Pipeline by NeoStem, Inc., H1 2015 58

Graft Versus Host Disease (GVHD)-Pipeline by Novartis AG, H1 2015 59

Graft Versus Host Disease (GVHD)-Pipeline by Omni Bio Pharmaceutical Inc., H1 2015 60

Graft Versus Host Disease (GVHD)-Pipeline by Pharmacyclics, Inc., H1 2015 61

Graft Versus Host Disease (GVHD)-Pipeline by Pharmicell Co., Ltd., H1 2015 62

Graft Versus Host Disease (GVHD)-Pipeline by Pluristem Therapeutics Inc., H1 2015 63

Graft Versus Host Disease (GVHD)-Pipeline by R-Tech Ueno, Ltd., H1 2015 64

Graft Versus Host Disease (GVHD)-Pipeline by REGiMMUNE Corporation, H1 2015 65

Graft Versus Host Disease (GVHD)-Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 66

Graft Versus Host Disease (GVHD)-Pipeline by Sarepta Therapeutics, Inc., H1 2015 67

Graft Versus Host Disease (GVHD)-Pipeline by Seattle Genetics, Inc., H1 2015 68

Graft Versus Host Disease (GVHD)-Pipeline by Sigmoid Pharma Limited, H1 2015 69

Graft Versus Host Disease (GVHD)-Pipeline by Soligenix, Inc., H1 2015 70

Graft Versus Host Disease (GVHD)-Pipeline by Spherium Biomed S.L., H1 2015 71

Graft Versus Host Disease (GVHD)-Pipeline by Targazyme, Inc., H1 2015 72

Graft Versus Host Disease (GVHD)-Pipeline by Therapix Biosciences Ltd, H1 2015 73

Graft Versus Host Disease (GVHD)-Pipeline by Tobira Therapeutics, Inc., H1 2015 74

Graft Versus Host Disease (GVHD)-Pipeline by Xenikos B.V., H1 2015 75

Assessment by Monotherapy Products, H1 2015 76

Assessment by Combination Products, H1 2015 77

Number of Products by Stage and Target, H1 2015 79

Number of Products by Stage and Mechanism of Action, H1 2015 82

Number of Products by Stage and Route of Administration, H1 2015 85

Number of Products by Stage and Molecule Type, H1 2015 87

Graft Versus Host Disease (GVHD) Therapeutics-Recent Pipeline Updates, H1 2015 205

Graft Versus Host Disease (GVHD)-Dormant Projects, H1 2015 288

Graft Versus Host Disease (GVHD)-Dormant Projects (Contd..1), H1 2015 289

Graft Versus Host Disease (GVHD)-Dormant Projects (Contd..2), H1 2015 290

Graft Versus Host Disease (GVHD)-Dormant Projects (Contd..3), H1 2015 291

Graft Versus Host Disease (GVHD)-Discontinued Products, H1 2015 292

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2015 16

Number of Products under Development for Graft Versus Host Disease (GVHD)-Comparative Analysis, H1 2015 17

Number of Products under Development by Companies, H1 2015 18

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Products, H1 2015 26

Assessment by Monotherapy Products, H1 2015 76

Number of Products by Top 10 Targets, H1 2015 78

Number of Products by Stage and Top 10 Targets, H1 2015 78

Number of Products by Top 10 Mechanism of Actions, H1 2015 81

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 81

Number of Products by Top 10 Routes of Administration, H1 2015 84

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 85

Number of Products by Top 10 Molecule Types, H1 2015 86

Number of Products by Stage and Top 10 Molecule Types, H1 2015 87

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbGenomics International, Inc.

Adienne Pharma & Biotech

Alder Biopharmaceuticals Inc.

Alexion Pharmaceuticals, Inc.

Apceth GmbH & Co. KG

Athersys, Inc.

Bellicum Pharmaceuticals, Inc.

Biogen Idec Inc.

Dr. Falk Pharma GmbH

Enlivex Therapeutics Ltd

Escape Therapeutics, Inc.

F. Hoffmann-La Roche Ltd.

Generon (Shanghai) Corporation Ltd.

Idera Pharmaceuticals, Inc.

ImmuNext, Inc.

Immunomedics, Inc.

Jazz Pharmaceuticals plc

Kadmon Corporation, LLC

Kamada Ltd.

Kymab Limited

Lycera Corp.

Mesoblast Limited

Millennium Pharmaceuticals, Inc.

MSM Protein Technologies, Inc.

Neopharm Ltd.

NeoStem, Inc.

Novartis AG

Omni Bio Pharmaceutical Inc.

Pharmacyclics, Inc.

Pharmicell Co., Ltd.

Pluristem Therapeutics Inc.

R-Tech Ueno, Ltd.

REGiMMUNE Corporation

Rigel Pharmaceuticals, Inc.

Sarepta Therapeutics, Inc.

Seattle Genetics, Inc.

Sigmoid Pharma Limited

Soligenix, Inc.

Spherium Biomed S.L.

Targazyme, Inc.

Therapix Biosciences Ltd

Tobira Therapeutics, Inc.

Xenikos B.V.

Graft Versus Host Disease (GVHD) Therapeutic Products under Development, Key Players in Graft Versus Host Disease (GVHD) Therapeutics, Graft Versus Host Disease (GVHD) Pipeline Overview, Graft Versus Host Disease (GVHD) Pipeline, Graft Versus Host Disease (GVHD) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com